Aurobindo Pharma reported a 26% year-on-year increase in net profit to ₹1,033 crore for the June quarter, driven by strong demand in US and European markets. The company also announced a structural merger of its Eugia subsidiary units to improve operational efficiency. Shares closed 1.83% higher at ₹1,615.00, reflecting positive market reaction to the results.
Aurobindo Pharma reported a consolidated net profit of ₹1,033 crore for the June quarter of fiscal year 2027, marking a 26% increase compared to the same period last year. The company's revenue from operations grew by 16% to ₹9,150 crore, outpacing market expectations. This growth was fueled largely by the company's international operations, which contributed 91% of the total revenue.
The United States market remains a key contributor, delivering 8.1% year-on-year growth to ₹3,770 crore, supported by the launch of 10 new products during the quarter. The company has filed 896 Abbreviated New Drug Applications (ANDAs) with the US Food and Drug Administration (USFDA) as of June 30, 2026, with 737 final approvals and 33 tentative approvals secured. Europe also showed strong performance, with revenue rising 25.6% year-on-year to ₹2,937 crore.
In a strategic move to simplify its organizational structure, the company’s board approved the merger of its wholly-owned subsidiaries, Eugia Steriles Pvt. Ltd. and Eugia SEZ Pvt. Ltd., with Eugia Pharma Specialities Ltd. The company plans to file this amalgamation with the National Company Law Tribunal (NCLT) in Hyderabad. Management indicated that this consolidation is intended to streamline the group’s structure, reduce administrative overheads, and improve operational synergies within its sterile injectables and oncology business segments.
While the company reported strong financial growth, the business remains sensitive to regulatory developments. Investors frequently track the USFDA's regulatory status at its manufacturing sites. The company continues to manage Official Action Indicated (OAI) classifications at its Units I and III facilities. Future profitability may also depend on managing raw material and solvent costs, as well as navigating currency fluctuations, particularly the Euro against the Indian Rupee.
The stock market reacted positively to the update, with shares closing at ₹1,615.00 on August 5, 2026, up 1.83% for the day. Shareholders and analysts will likely look for further updates during the upcoming earnings call scheduled for August 6, 2026, particularly regarding management's guidance on sustaining these margins and progress on resolving outstanding USFDA regulatory matters.